When did ARS Pharmaceuticals, Inc. report Q4 2024 earnings?

ARS Pharmaceuticals, Inc. (SPRY) reported Q4 2024 earnings on March 20, 2025 before market open.

What were ARS Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?

ARS Pharmaceuticals, Inc. reported revenue of $86.6M and diluted EPS of $0.52 for Q4 2024.

Did ARS Pharmaceuticals, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $12.8M by $73.7M. EPS beat the consensus estimate of $-0.04 by $0.56.

Where can I find ARS Pharmaceuticals, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-042320) directly on SEC EDGAR. The filing index links above go to sec.gov.

ARS Pharmaceuticals, Inc. SPRY Q4 2024 Annual earnings

Reported March 20, 2025 · Before market open

Revenue$86.6MBeat by $73.7M Diluted EPS$0.52Beat by $0.56

Revenue estimate$12.8M

EPS estimate-$0.04

Next report

Aug 12, 2026 (in a month)

Revenue estimate$31.3M

EPS estimate-$0.48

Financials

Q4 2024

Income statement

See full

Revenue$86.6M—

Net income$49.9M+797%

EPS (diluted)$0.51+829%

Balance sheet

See full

Cash & equivalents$50.8M-28.4%

Total debt$42.0K-84.7%

Total equity$256.8M+11.3%

Total assets$351.2M+50.6%

Cash flow

See full

Operating cash flow$42.0M+341%

CapEx$302.0K—

Free cash flow$41.7M+341%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$1.03B+94.1%

Enterprise value$974.53M+113%

P/E128.2×—

P/S11.5×-17,600×

Profitability

See full

Net margin9%+4.5pp

FCF margin14.6%+7.3pp

Returns & leverage

See full

Return on equity3.3%+1.8pp

Debt / equity0×0.0×

Current ratio14.3×-82.7×

Segments

By product

See full

Revenue Under Collaboration Agreements$79.5M—

Revenue Under Supply Agreements$365.0K—

By geography

See full

Non Us$20.5M—

Versus estimates

Revenue

Q1 2026$22.7MBeat by $481.0K Q4 2025$28.1MBeat by $2.5M Q3 2025$32.5MBeat by $6.9M Q2 2025$15.7MMiss by $12.0M Q1 2025$8.0MMiss by $6.7M

Q4 2024$86.6MBeat by $73.7M

Diluted EPS

Q1 2026-$0.61Miss by $0.08 Q4 2025-$0.42In line Q3 2025-$0.52Miss by $0.07 Q2 2025-$0.46Miss by $0.05 Q1 2025-$0.35In line

Q4 2024$0.52Beat by $0.56

Ask the moment ARS Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ARS Pharmaceuticals, Inc. report Q4 2024 earnings?: ARS Pharmaceuticals, Inc. (SPRY) reported Q4 2024 earnings on March 20, 2025 before market open.
What were ARS Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?: ARS Pharmaceuticals, Inc. reported revenue of $86.6M and diluted EPS of $0.52 for Q4 2024.
Did ARS Pharmaceuticals, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $12.8M by $73.7M. EPS beat the consensus estimate of $-0.04 by $0.56.
Where can I find ARS Pharmaceuticals, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-042320) directly on SEC EDGAR. The filing index links above go to sec.gov.